Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Augmentation versus switch in treatment-resistant major depressive disorder
2017-004169-28Phase 4Terminated
- Sponsor
- Fondazione Santa Lucia IRCCS
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of aripiprazole and venlafaxine in major depressive disorder (MDD) and treatment-resistant depression (TRD) (2 arms), sponsored by Fondazione Santa Lucia IRCCS. Primary endpoint: Clinical improvement and quality of life. Started Jun 2021; status: terminated.
02
Drugs
aripiprazolevenlafaxine
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on 2017-004169-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004169-28.